Lomecel-B

Product

Last mentioned: Mar 19, 2026

Timeline

  1. Q4 2025 Earnings Call

    Management discussed clinical progress of Lomecel-B and financial outlook.

  2. Capital Raise

    Entry into a material definitive agreement for the sale of unregistered equity securities.

  3. NASDAQ Compliance Notice

    Longeveron received notice of failure to satisfy NASDAQ listing rules.

Stories mentioning Lomecel-B 1

pharma Neutral

Longeveron Navigates Capital Constraints Amid Lomecel-B Clinical Progress

Longeveron Inc. (LGVN) reported Q4 2025 results, highlighting clinical advancements in its Lomecel-B cell therapy for rare pediatric heart conditions and Alzheimer's disease. Despite clinical momentum, the company is managing significant financial headwinds, including a recent NASDAQ compliance notice and a subsequent capital raise in March 2026.

4 sources